This agreement gives BizCom non-exclusive rights to market and sell Optimer discovery and development services in Japan. 

The Optimer platform consists of three integrated discovery processes that together increase the potential target range of Optimer binders. These nucleic acid-based affinity ligands deliver a range of advantages to scientists, including faster discovery, increased batch consistency and increased stability, removing the need for freezers and providing a longer shelf life than protein-based alternatives. 

BizCom Japan, Inc. will use its extensive experience, and sales and marketing expertise, in Japan’s life sciences space to market Aptamer Group’s services in the region.

Dr Arron Tolley, CEO of Aptamer Group said: “We are delighted to partner with BizCom Japan to establish a clear route to market for Optimer discovery services in Japan, one of the largest pharma and medtech markets. This is an important market for Aptamer Group; BizCom Japan is an excellent partner and is associated with well-known, established suppliers. It has an excellent reputation for customer support and a wide network throughout Japan.” 

Dr Hiroyasu Nakatani, Executive Managing Director of BizCom Japan said: “We are pleased to distribute custom Optimer services into the Japanese market. Optimer binders are unique affinity ligands showing specific binding activity, stability and offering novel solutions to researchers that cannot be achieved with alternative ligands, such as antibodies. We are delighted to bring this new technology to scientists in Japan, to offer increased support to the life science market.”